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SUMMARY 
The abuse of phenacetin-containing analgesic mixtures has been 
linked epidemiologically with nephrotoxicity and carcinogenicity 
in man. 
In addition, clinical and histopathological tests after chronic 
administration of phenacetin in man and animals have indicated 
that it is nephrotoxic and carcinogenic. Furthermore, it has a 
chemical similarity to other known carcinogenic arylamides. 
However, the induction of toxicity with phenacetin remains a 
controversial subject. 
A number of chronic dosing studies with phenacetin have been 
carried out to demonstrate the ability of the drug to induce 
carcinogenesis and nephropathy. However, none have sought to 
explain the reasons for the chronic nature of phenacetin 
toxicity on the basis of the increased formation of toxic 
metabolites after continued administration of the drug. In the 
present chronic daily-dosing study with phenacetin in the rat, 
the metabolism of the drug was monitored by analysing urine 
samples at regular weekly intervals. Particular attention was 
paid to the formation of N-hydroxyphenacetin, which has been 
implicated in phenacetin carcinogenicity. 
The metabolism of phenacetin was monitored in five groups of 
Hooded Wistar rats. Each group was subjected to a different 
treatment. The purpose was to elucidate the effects of the size 
of the dose, duration of treatment, influence of commonly co- 
administered drugs (aspirin, caffeine) and the influence of a 
sulfation inhibitor (pentachlorophenol) on the metabolism of 
phenace tin. 
The 	metabolic 	trends 	indicated 	auto-induction 	of 	N- 
hydroxylation, evidenced by the increased formation of N-
hydroxyphenacetin in all treatments. The induction was most 
pronounced with the large dose of phenacetin and, significantly, 
was prominent with the co-administration of aspirin at the lower 
dose of phenacetin. 
Paracetamol-sulfate was the major metabolite of phenacetin in 
the rat, while paracetamol-glucuronide and free paracetamol were 
the other products of the deethylation pathway of phenacetin. 
The mercapturate and cysteinyl conjugates were not detected. 
Pentachlorophenol, a known inhibitor of sulfation, did not block 
sulfation completely. The partial suppression of sulfation with 
pentachlorophenol resulted in the increased formation of 2- 
hydroxy-p-phenetidine and yielded a larger fraction of unchanged 
phenacetin in the urine. 
The metabolism of p-phenetidine, a deacetylated metabolite of 
phenacetin, was followed in freshly isolated rat hepatocytes. 
The biotransformation of p-phenetidine to phenacetin and 2- 
hydroxyphenetidine indicated that N-acetylation was significant 
in the Hooded Wistar rat. However, N-acetylation and aromatic 
hydroxylation did not fully account for the disappearance of p-
phenetidine from the in vitro system. 
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CHAPTER 1. 	INTRODUCTION 
1.1. ANALGESIC ABUSE-ASSOCIATED TOXICITY AND PHENACETIN 
Phenacetin, a widely used antipyretic-analgesic, was first 
introduced for the treatment of pain in 1887. It continued to be 
extensively 	used, 	chiefly as a constituent in analgesic 
mixtures, until recently (Flower et al., 1980). 	Analgesic 
nephropathy. has 	been recognized as a frequent clinical, 
radiological and autopsy finding in Scandinavia (Lindeneg et 
al.,1959; Bengtsson,1962; Harvald,1963), Australia (McCutcheon, 
1962; Jacobs and Morris,1962; Dawborn et al.,1966; Kincaid-
Smith,1969), Britain (Jacobs,1964; Sanerkin and Weaver, 1964), 
United States of America (Reynolds and Edmondson,1963) and 
Canada (Lakey,1961). .However, controversy persists with regard 
to the involvement of phenacetin in the development of analgesic 
nephropathy (Freeland,1975; Nanra,1976). 
1.1.1. ANALGESIC-INDUCED NEPHROPATHY IN MAN  
Analgesic abuse, now defined as an intake in excess of 1 g of an 
analgesic per day, for one year, by Bengtsson et al. (1978), was 
first identified as a problem in Sweden, with particular 
reference to phenacetin, in 1918 (Grimlund,1963). However, it 
was not until 1953 that Spuhler and Zollinger (1953) pointed out 
that analgesic drugs could cause chronic renal disease. It has 
since been an area of concern demanding intensive research 
effort to explain the induction of toxicity by analgesics. 
Dubach and co-workers conducted an epidemiological study of the 
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abuse of analgesics in a Swedish population, over a period of 
ten years from 1968-1979, and concluded that heavy users of 
analgesic mixtures over the course of a decade exhibited a 
higher incidence of both abnormal kidney function and kidney-
related mortality, though the absolute incidences remained small 
even among heavy users (Dubach et al.,1968; 1971; 1975; 1983). 
Further evidence implicating analgesics in nephrotoxicity was 
provided by the studies of Duggin (1977), Bengtsson et al. 
(1978), Kincaid-Smith (1978), Bengtsson and Angervall (1979) and 
Prescott (1966; 1982), who examined the relationship between 
ingestion of analgesics and the development of renal disease. 
Analgesic abuse-associated nephropathy, as the condition is 
known and described today, is affected by addiction or abuse of 
alcohol, cigarettes, barbiturates, hypnotics, tranquilizers and 
laxatives (Prescott,1976; Kincaid-Smith,1978; Nanra et al., 
1978). 
1.1.2. ANALGESIC-INDUCED CARCINOMA IN MAN 
Phenacetin has also been implicated as a cause of carcinoma of 
the renal pelvis. Hultengren et al. (1965) were the first to 
suggest the association of analgesic abuse with carcinoma in 
Sweden. They were followed by researchers in other countries 
(Taylor,1972; Liu et al.,1972; Bengtsson et al.,1978; Lornoy et 
al.,1979), who provided further evidence on the relationship 
between analgesic abuse and tumors of the renal pelvis. 
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1.1.3. PHENACETIN-INDUCED TOXICITY IN MAN 
The decline in the use of phenacetin is also attributed to the 
methemoglobinemia, sulfhemoglobinemia and hemolytic anemia it 
produces on chronic administration (Flower et al.,1980), as well 
as nephropathy (Spuhler and Zollinger,1953) and 'neoplasia (Liu 
et al.,1972). Although the adverse effects produced by 
phenacetin are reversed in most instances on withdrawal of the 
drug, they still remain an alarming testimony of drug-induced 
pathophysiological disorders. The fact that phenacetin was the 
one common ingredient in all combination analgesics responsible 
for renal impairment (Koutsaimanis and de Wardener,1970), was 
used to incriminate it as the compound responsible for the 
increased incidence of tumors of the renal pelvis (Hultengren et 
al.,1965; Bengtsson et al.,1968; Angervall et al.,1969; 
Johansson et a1,1974; Johansson and Wahlqvist 1977) interstitial 
nephritis and renal papillary necrosis (Nordenfelt and Ringertz, 
1961). It was also seen that the withdrawal of phenacetin from 
analgesic preparations in Sweden in 1961 resulted in fewer 
deaths from renal failure among analgesic abusers in subsequent 
years (Nordenfelt,1972), an observation that added credence to 
the alleged toxicity of phenacetin. However, recent data 
suggests that phenacetin may not be the only toxic analgeaic 
(Sec. 1.1.5). 
1.1.4. PHENACETIN-INDUCED TOXICITY IN ANIMALS 
In earlier animal experiments, phenacetin failed to manifest any 
noteworthy toxicity. Neither phenacetin nor most of its 
metabolites were proven. to be significantly nephrotoxic in 
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animals (Calder et al.,1971). Only minimal renal papillary 
necrosis has been produced in animals by administration of 
phenacetin alone, even in large doses (Clausen,1964; Fordham et 
al.,1965). Although renal pelvic tumors in laboratory animals 
have not been encountered after long-term administration of 
phenacetin, it must be borne in mind that several bladder 
carcinogens exhibit species specificity, and failure to produce 
carcinoma in animals is not sufficient proof of their safety in 
man (Nery,1971a). For example, 2-naphthylamine, a known 
carcinogen in man, does not produce malignancies in rats, 
rabbits, cats and mice (Bonser et al.,1959). However, in recent 
years phenacetin has been shown to cause hepatic necrosis in 
hamsters (Mitchell et al.,1975; 1976; Nelson et al.,1978). 
Chronic administration of phenacetin to rats in the diet induced 
urothelial hyperplasia of the renal papillae, earduct tumors and 
mammary adenocarcinomas (Johansson and Angerval1,1976), nasal 
carcinomas and urinary tract tumors (Isaka et al.,1979) and had 
a carcinogenic effect on most tissues (Johansson,1981). These 
studies suggested a more general carcinogenic effect of 
phenacetin in the rat. The rat therefore has been chosen as a 
suitable animal model for the investigation of the metabolism of 
phenacetin to putative toxic metabolites. 
1.1.5. TOXICITY INDUCED BY OTHER ANALGESICS  
It should be noted, however, that renal papillary necrosis has 
been produced by aspirin, phenacetin and caffeine mixtures and 
by aspirin alone, more readily than by phenacetin itself 
(Abrahams et al.,1964; Saker and Kincaid-Smith,1969; Nanra and 
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Kincaid-Smith,1970; 	1972a; 	1973b; Nanra et al.,1970). Lesions 
were seen to develop more frequently at low dose levels with 
aspirin than with phenacetin (Axelsen,1976). The substantial 
increase in excretion of renal tubular cells (a gauge of renal 
damage) observed in healthy volunteers receiving aspirin, 
compared with those receiving phenacetin, was taken as further 
evidence of the greater nephrotoxic risk of aspirin (Prescott, 
1965) in comparison to phenacetin. Cognisance must also be 
taken of the renal papillary necrosis reportedly induced in 
animals with other analgesics and nonsteroidal anti-inflammatory 
drugs including phenazone (Nanra and Kincaid-Smith,1973a) 
indomethacin and phenylbutazone (Nanra et al.,1970; Arnold et 
al.,1974), amidopyrine (Brown and Hardy,1968), mefenamic acid 
(Nanra et al.,1970) and the sole responsibility of phenacetin 
for such toxicity diminished. 
Although in no cases reported have patients consumed phenacetin 
alone, the incrimination of phenacetin as the nephrotoxic and 
carcinogenic entity in analgesic mixtures has been made on the 
presumption that its metabolism is similar to that of known 
carcinogenic amines (Miller and Miller,1966a; 1966b; Bengtsson 
et al.,1978). The metabolism of phenacetin has been 
investigated in several species, including rats, hamsters, 
rabbits and human subjects (Smith and Griffiths,1976; Kuntzman 
et al.,1977; Prescott,1980; Vaught et al.,1981). However, there_ 
remains the need to elucidate, in greater depth, its metabolism 
after chronic administration. 
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1.2. METABOLITES OF PHENACETIN 
Several studies have 	been 	carried 	out to identify the 
metabolites of phenacetin ,since Brodie and Axelrod (1949) and 
Smith and Williams (1949) independently found N-acetyl-p-
aminophenol (paracetamol,APAP) as the major and p-phenetidine 
(PN) as the minor metabolite of phenacetin. Jagenburg and 
Toczko (1964) isolated S-(1-acetamido-4-hydroxyphenyl)cysteine 
as a urinary metabolite of phenacetin in man, while Klutch et 
al. (1966) identified 2-hydroxyphenacetin in the urine of 
humans, dogs and cats. Buch et al. (1966,1967) detected 2- 
hydroxyphenetidine (2HPN), in human and rat urine and 3- 
hydroxyphenacetin in the urine of rats given phenacetin. 
N-hydroxyphenacetin (NHP), whose conjugates are postulated to be 
potential carcinogens, was reportedly first detected in'the 
urine of cats and dogs treated with phenacetin (Klutch et al., 
1966). It was further found in the urine of humans and dogs by 
Klutch and Bordun (1960), but had not been indisputably 
demonstrated to be a metabolite of phenacetin in vivo  
(Weisburger and Weisburger, 1973; Hinson and Mitchell, 1976), 
until 1981 in the rat (McLean et al., 1981). Kiese and Lenk 
(1969) detected 4-ethoxyglycolanilide as a phenacetin metabolite 
in the urine of rabbits. 	Nery (1971b) found N-acetyl-S- 
ethylcysteine, 	acetamide and quinol to be metabolites of 
phenacetin in the rat. 	Focella et al. (1972) identified 4- 
hydroxy-3-methylthio-acetanilide, while Fischbach et al. (1977) 
found N-[4-(2-hydroxyethoxy)pheny1]-acetamide in the urine of 
rats and rabbits after administration of phenacetin. 
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4-Acetaminophenoxyacetic acid was detected as a new metabolite 
of phenacetin by Dittman and Renner (1977) and 3-methylthio-4- 
hydroxyacetanilide by Klutch et al. (1978). 
Recently there has been considerable interest in the disposition 
of phenacetin and its metabolites in animals and in man 
(Prescott et al.,1968; Kampffmeyer,1974; Raaflaub and Dubach, 
1975; Welch et al.,1976) with relevance to enzyme induction, 
which increased the metabolism of phenacetin (Pantuck et al., 
1974). Habitual smoking is reported to enhance the metabolism 
of phenacetin (Pantuck et al.,1972) and dietary habits such as 
the consumption of charcoal broiled beef have been known to 
increase the metabolism of phenacetin (Conney et al.,1976). The 
potential interaction of reactive metabolites of phenacetin with 
biological macromolecules has also been investigated in recent 
years (Mulder et al.,1977; Hinson et al.,1977). 
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1.3. BIOTRANSFORMATION OF PHENACETIN 
The metabolic biotransformations 	by 	which 	phenacetin is 
hydroxylated, oxidatively deethylated, N-deacetylated and 
conjugated by hepatic microsomal enzymes (Brodie and Axelrod, 
1949; Smith and Williams,1949; Klutch et a1,1966; Buch et al., 
1967; Prescott,1969; Nery,1971b; Focella et al.,1972; Mrochek 
et al.,1974) are depicted in Fig. 1. 
1.3.1.1. PARACETAMOL: METABOLITE-MEDIATED TOXICITY 
Paracetamol is the major, immediate metabolite of phenacetin 
(Brodie and Axelrod,1949) and is a widely used antipyretic-
analgesic in its own right. It is known to be hepatotoxic in 
massive overdosage (Boyd and Bereczky,1966; Prescott et al., 
1971; Mitchell et al.,1973a; Kleinman et al.,1980) and 
nephrotoxic following prolonged abuse (Duggin and Mudge,1976; 
Mitchell et al.,1977; Mudge et al.,1978) due to metabolic 
activation to a highly reactive toxic metabolite(Mitchell et 
al.,1973a; 1973b; Jollow et al.,1973; Potter et al. 1973; 
Hinson et al.,1980; Hinson and Gillette,1980). 
The implication of a reactive metabolite in paracetamol-induced 
toxicity was first disclosed by the studies of Mitchell et al. 
(1973a), who showed that paracetamol produced an increased 
incidence of hepatic necrosis in rats in which drug metabolizing 
enzymes were induced by prior treatment with phenobarbitone or 
3-methylcholanthrene, and that a decrease in the incidence and 
severity of toxicity followed the use of inhibitors of drug 
metabolism such as piperonyl butoxide or cobaltous chloride 
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(Potter et al., 1974) and recently, cimetidine (Mitchell et al., 
1981). This reactive metabolite is formed by a microsomal 
cytochrome P-450 mixed function oxidase and is detoxified by 
conjugation with glutathione (Mitchell et al.,1973b; Jollow et 
al., 1973). 
Paracetamol has also been recognized as a nephrotoxic metabolite 
of phenacetin by other workers such as Nanra et al. (1980) and 
Margetts (1976). Further observations that patients who 
persisted in abusing analgesic mixtures in which phenacetin was 
replaced with salicylamide or paracetamol still presented with 
typical analgesic nephropathy and renal failure (Krishnaswamy 
and Nanra,1976; Nanra et al.,1978) corroborates the nephrotoxic 
potential of paracetamol. 
In animal studies Nanra et al. (1970) and Nanra and Kincaid- 
Smith (1970; 1972b) established 	a similarity between the 
nephrotoxicity caused by phenacetin and 	that produced by 
paracetamol when administered alone or in combination with other 
analgesic constituents. It seems apparent, therefore, that if 
the toxicity caused by the chronic ingestion of phenacetin alone 
is accepted, then it is metabolite-mediated and could be at 
least partly due to one or more of the highly reactive 
metabolites of paracetamol (Sec. 1.3.1.2) 
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1.3.1.2. PARACETAMOL : POSTULATED REACTIVE METABOLITES 
Jollow et al. (1973) and Mudge et al. (1978) established that 
acute overdosage of paracetamol in rats and mice ultimately 
resulted in covalent binding of the reactive metabolite to 
tissue macromolecules in the liver and kidney, after the 
depletion of glutathione. Although a study of urinary 
metabolites has indicated that reactive intermediates had 
reacted with cellular glutathione (Hinson et a1,1980; Jollow et 
al.,1974a) none of the postulated toxic intermediates have been 
identified as being solely responsible for the toxicity, during 
the course of in vivo and in vitro (microsomal) experimentation. 
1.3.1.2.1. N-HYDROXYPARACETAMOL 
Among 	the proposed toxic metabolites (Fig. 	2) 	was 	N- 
hydroxyparacetamol (NHAPAP).This had been earlier shown to 
dehydrate to N-acetyl-p-benzoquinoneimine (NAQ), a compound 
known to react with cellular glutathione and protein and 
postulated to be toxic (Jollow et al.,1974a). Therefore NHAPAP 
was believed to be the toxic reactive intermediate of 
paracetamol (Mitchell et al., 1973a; 1973b; Jollow et al.,1973; 
Potter et al.,1973; 1974). This concept was questioned because 
NHAPAP was not detected as a metabolite of paracetamol although 
it is formed from phenacetin (Hinson et al.,1979a; Nelson et 
al.,1980). At a physiological pH NHAPAP did not rapidly 
dehydrate to NAQ (Healey et al.,1978; Gemborys et al.,1980) and 
was only slightly more toxic than APAP (Healey et al.,1978), 
hence could not be regarded as its toxic intermediate. 
Page 11 
1.3.1.2.2. 3-4,EPDXIDE-PARACETAMOL  
The implication of 3,4-epoxy-paracetamol as the toxic metabolite 
(Andrews et al.,1976) was negated by the investigations of 
Hinson et al. (1980) and Hinson and Gillette (1980). They 
demonstrated through mass spectral studies that atmospheric 
oxygen was not incorporated into the paracetamol-glutathione 
adduct, which would otherwise be expected were paracetamol to 
form an arene oxide in the 3,4-position followed by 
rearrangement to NAQ prior to conjugation (Hinson et al.,1977). 
Also when p-18-0-paracetamol was used as a substrate, all of the 
18-0 was retained in the paracetamol-glutathione complex (Hinson 
et al.,1979c). The evidence does not indicate 3,4-epoxidation 
of paracetamol, but similar experiments with phenacetin did 
reveal 3,4-epoxidation as one mechanism of microsomal activation 
of phenacetin to a reactive metabolite (Hinson et al.,1979a). 
A theory of free radical mediated toxicity has been proposed but 
is yet to be proved (Andrews et al.,1976). 
1.3.1.2.3. N-ACETYL-p-BENZOQUINONEIMINE  
The other proposed toxic intermediate for paracetamol in the 
literature 	to 	date 	is 	the 	electrophile 	N-acetyl-p- 
benzoquinoneimine (NAQ). NAQ, which covalently binds with 
protein (Mulder et al.,1978) and glutathione (Hinson et al., 
1979c), has been generally accepted as the most likely ultimate 
toxic intermediate of paracetamol (Hinson et al., ,1979a; Nelson 
et al.,1980; Calder et al.,1981). Though it was supposedly 
formed from NHAPAP, a toxic reactive species in itself (Jollow 
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et al.,1974a), the evidence (Hinson et al.,1979a; Nelson et al., 
1980) indicates that it must be formed from still another 
reactive source because NHAPAP, with a relatively slow 
decomposition (Hinson et al.,1979a) which would enable it to be 
detected if it were formed, is not an intermediate involved in 
the metabolism of paracetamol in vitro (Hinson et al.,1979a; 
Nelson et al.,1980) or in vivo (Gemborys and Mudge,1981). 
Calder et al. (1981) further confirmed that no N-hydroxylated 
metabolites resulted from paracetamol administration and 
postulated the concept of hepatotoxicity and nephrotoxicity 
being directly mediated by an oxidation of paracetamol to the 
toxic reactive 	intermediate NAQ by the cytochrome P-450- 
dependent mixed function oxidase. 	However, NHAPAP could still 
be a reactive toxic metabolite of phenacetin, as it has been 
found to be present as a metabolite of phenacetin and though 
believed earlier to be formed by the N-hydroxylation of 
paracetamol, it has since been shown to be formed by the 
subsequent de-ethylation of N-hydroxylated phenacetin (Hinson et 
al.,1979a). An in vivo measurement of NHP formation would 
therefore reflect 	the 	extent 	to which postulated toxic 
metabolites of paracetamol could be formed from phenacetin. 
1.3.1.3. p-AMINOPHENOL  
p-Aminophenol (PAP), identified as a urinary . metabolite of 
paracetamol and NHAPAP in the hamster (Gemborys and Mudge,1981) 
and known to be highly nephrotoxic though relatively non-
hepatotoxic (Green et al.,1969; Calder et al.,1971; Crowe et 
al.,1979; Newton et al.,1982) could be of toxicological interest 
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as well. It has of late been considered to be an immediately 
reactive nephrotoxic compound (Calder et al.,1979). 
1.3.1.4. CONJUGATES OF PARACETAMOL 
The major urinary metabolites of paracetamol, paracetamol-
glucuronide, paracetamol-sulfate and 3-mercapturate-paracetamol, 
occur in all species (Gemborys and Mudge,1981), with other 
metabolites being identified uniquely to a particular species. 
These are 4-hydroxyglycoanilide in rats (Smith and Griffiths, 
1976), 3-cysteinyl-paracetamol in man and mice (Mrochek et al., 
1974; Whitehouse et al.,1977), 3-sulfoxymethyl-paracetamol in 
hamsters (Wong et al.,1976), 3-thiomethyl-paracetamol in man and 
dog (Klutch et al.,1978), 3-methoxyparacetamol in man (Andrews 
et al.,1976) and 3-hydroxyparacetamol in man (Andrews et al., 
1976; Mrochek et al.,1974). 
1.3.2. p-PHENETIDINE  
N-deacetylation is considered to be an essential step in the 
precipitation 	of 	haemotoxicity 	by acetanilide 	analogues 
(Mitchell et al.,1973c). The N-deacetylation of phenacetin 
gives p-phenetidine (PN) as shown in Fig. 1. This is the second 
major direct metabolite of phenacetin. The subsequent 
metabolism of PN has not been adequately reported, although it 
has been suggested that it undergoes oxidation to quinones and 
aromatic nitrosoamines and it is known to cause 
methemoglobinemia by the formation of haemotoxic metabolites 
NHPN, 2HPN and PAP (Kiese,1966; Uehleke,1973). Evidence of its 
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existence as the second major metabolite of phenacetin and its 
disappearance in the metabolic process has been recorded using 
isolated hepatocyte systems (McLean,1978). The de-ethylated, N-
hydroxylated, nitrosated and 2-hydroxylated metabolites of PN 
have been reported (Brodie and Axelrod 1 1949), but their 
contribution to nephrotoxicity has not been determined. 
1.3.3. 2-HYDROXYPHENACETIN, 3-HYDROXYPHENACETIN  
and 2-HYDROXYPHENETIDINE 
The hydroxylated products of phenacetin, 2-hydroxyphenacetin 
(2HP), 3-hydroxyphenacetin (3HP) and 2-hydroxyphenetidine (2HPN) 
have been reported (Buch et al.,1966; 1967; Klutch et al.,1966) 
earlier. 2HP was devoid of antipyretic activity in rats and did 
not cause methemoglobinemia in dogs and in rats no abnormal 
gross or histological changes in kidney function or structure 
were produced on oral administration for prolonged period 
(Burns and Conney,1965). No toxicity has been reported with 2HP 
in the concentrations at which it is usually present. However, 
isolated cases of toxicity have been reported for 2HPN. Shahidi 
and Hemaidan (1969) presented a case where large amounts of 2HPN 
were present in the urine of a female patient who developed a 
severe hemolytic reaction. These abnormalities in respon-se were 
rare and familial. 
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1.3.4. N-HYDROXY METABOLITES  
Many toxic substances are generally detoxified within biological 
systems by conjugation with glucuronic acid by UDP-
glucuronyltransferase, or sulfation by sulfotransferase (Mulder 
and Scholtens,1977), or combination with glutaihione (GSH) 
(Mitchell et al.,1973b; 1974; Jollow et al.,1974b). Whether a 
compound would eventually prove to be toxic, would therefore 
depend on the extent to which the conjugating enzymes were 
active and the quantity of glutathione available for 
electrophilic "mopping up". 
In recent years attention has been focussed on the toxicity 
caused by arylamines. The arylamines have earned notoriety as 
compounds capable of undergoing hydroxylation by hepatic mixed 
function oxidases to yield the proximal carcinogenic N- 
arylhydroxylamines and N-arylhydroxamic acids (Baldwin and 
Smith,1965; Miller and Miller,1966a; Kiese,1966; Miller,1970; 
Weisburger and Weisburger,1973; Miller,1978). 
Several compounds possessing an N-hydroxyl group in their 
molecules, have been reported as carcinogenic compounds. N-
arylhydroxylamines such as N-hydroxy-2-naphthylamine, N-hydroxy-
4-aminobiphenyl (Radomski and Bri11,1970; 1971; Radomski et - 
al.,1977) and N-arylhydroxamic acids such as N-hydroxy-2- 
acetylaminofluorine (Miller et al.,1961; Razzouk et al.,1977), 
whose activated esters such as the sulfate, acetate and 
glucuronide, are strong electrophiles. These compounds have been 
shown to possess carcinogenic character reflected in their 
ability to bind to the nucleophilic groups in cellular 
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macromolecules (Scribner and Naimy,1973; 	Miller et al.,1974; 
Miller and Miller,1976). 
In specific cases of N-arylhydroxylamines and N-arylhydroxamic 
acids such as N-hydroxy-2-acetylaminofluorene (DeBaun et al., 
1970), N-hydroxy-N-methyl-4-aminobenzene (Kadlubar et al.,1976), 
N-hydroxy-4-acetylaminobiphenyl (Kriek,1971), N-hydroxy-N,N- 
diacetylbenzidine 	(Morton 	et 	al.,1980), 	N-hydroxy-2- 
acetylaminophenanthrene (Scribner and Naimy,1973) and N-
hydroxyphenacetin (Mulder et al.,1977), sulfation increased the 
toxicity of the parent compounds. 
The sulfate conjugates produced were highly reactive with tissue 
nucleophiles. Contrary to expectations of the detoxification 
role of sulfation in biological processes, sulfation of certain 
N-arylhydroxylamines and N-arylhydroxamic acids results in the 
formation of their reactive entities. 
The esterification of N-arylhydroxylamines and N-arylhydroxamic 
acids has been therefore regarded as an activation pathway 
leading to carcinogenesis for N-hydroxy compounds (Weisburger, 
1978). However, the carcinogenic character of a compound is not 
entirely explained by the occurrence of an N-hydroxyl group 
within its molecular structure (Weisburger,1978). 
Phenylhydroxylamine and N-hydroxysuccinimide are examples of 
such non-carcinogenic compounds. 
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1.3.4.1. N-HYDROXYPHENACETIN : A PROXIMAL CARCINOGEN  
NHP is an important metabolite of phenacetin, in terms of its 
carcinogenicity. It has been suggested to be the metabolite of 
phenacetin most likely to induce tumors due to its chemical 
similarity to the known carcinogenic N-arylhydroxamic acids 
(Calder and Williams,1975). It has also been suggested as the 
'metabolic product of phenacetin which could best account for the 
covalent binding of phenacetin to cell protein (Nery,1971a) and 
as an intermediate in the formation of other products of 
phenacetin metabolism (Nery,1971b; Calder et al.,1974). The 
mechanism of the renal and hepatic toxicity of phenacetin has 
been proposed to occur in two steps, N-hydroxylation followed by 
conjugation and subsequent decomposition to a reactive 
intermediate (Mulder et al.,1977; 1978). The same metabolic 
sequence activates the carcinogen, 2-acetylaminofluorene. 
Evidence of in vitro N-hydroxylation by liver microsomes has 
been demonstrated in hamsters (Hinson and Mitche11,1976), 
rabbits (Fischbach et al.,1977), mice (Kapetanovic et al.,1979) 
and in vivo experiments in rats (McLean et al.,1981). Evidence 
of conjugation with sulfate and glucuronide in vitro by rat 
liver enzymes, and subsequent decomposition has been contributed 
by Mulder et al. (1977,1978). Calder et al. (1976) showed that, 
. in chronically treated rats NHP induced neoplasia and tumors of 
the liver were a direct manifestation of its carinogenicity. A 
quantitative estimation of NHP over a prolonged study period 
would therefore provide information on the increased formation 
or accumulation of this metabolite, which may ultimately relate 
to the toxicity of the parent analgesic compound, phenacetin. 
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1.4. CHRONIC DOSING STUDIES 
Since toxicity from phenacetin is only seen after prolonged 
administration of the drug, progressive monitoring of metabolic 
changes over extended periods, accompanied by pathophysiological 
surveillance and toxicokinetic evaluation would prove helpful in 
determining the cause of phenacetin-induced carcinogenicity and 
nephrotoxicity. 
The effect of the size of the chronic dose on metabolism and or 
on the development of carcinoma or nephropathy could also be 
included in such investigations. The development of tolerance 
or increased susceptibility to phenacetin-toxicity could further 
be closely examined as there have been reports of related 
analogues of phenacetin being able to protect animals from 
paracetamol-induced hepatotoxicity (Kapetanovic,1979). Chronic 
dosing with phenacetin itself has been shown to cause tolerance 
and protection from hepatotoxicity (Boyd and Hottenroth,1968; 
Boyd,1971; Carro-Ciampi,1971; 1972; Kapetanovic and Mieyal, 
1979). The metabolic interference likely to be caused by other 
drugs or compounds co-administered with phenacetin could also be 
investigated. 
1.4.1. ALTERED METABOLISM WITH CHRONIC DOSING  
Carro-Ciampi (1972), in chronic studies with phenacetin, further 
demonstrated tolerance to phenacetin-induced hypothermia in both 
albino rats and guinea pigs, after repeated daily 
administration. Irrespective of the daily dose used, tolerance 
developed in guinea pigs more slowly than in albino rats. In 
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acute phenacetin toxicity death is due to hypothermic coma as 
well as cyanosis, respiratory depression and cardiac arrest and 
therefore, when tolerance develops to phenacetin hypothermia, 
animals are able to survive normally lethal doses of the drug 
(Boyd,1959; 1960; Boyd et al., 1969; Carro-Ciompi, 1971). 
These chronic-dose studies (Carro-Ciampi, 1972) indicated a 
halving of plasma levels of phenacetin within 10 days of 
initiation of phenacetin administration. This effect developed 
more slowly in guinea pigs, and was accompanied by a marked 
increase in PN levels. This would account for the chronic 
hemolytic anemia (Schnitzer and Smith, 1966) and 
methemoglobinemia (Brodie and Axelrod,1949) seen more commonly 
in guinea pigs. 
One hundred day LD 50 studies provide further examples of how 
chronic dosing studies (Boyd and Hottenroth,1968; Boyd and 
Carro-Ciampi,1970; Boyd,1971) undertaken to stress the 
importance of toxicity caused by prolonged administration of 
phenacetin, could be beneficial. 
1.4.2. INFLUENCE OF DOSE SIZE, ADMINISTRATION ROUTE,  
SPECIES VARIATION AND DURATION OF TREATMENT  
Few investigations have been carried out to examine factors such 
as dose, administration route and species which could probably 
affect the metabolism of phenacetin and its alleged toxicity 
with chronic use. Smith and Timbrell (1974) carried out such 
investigations and found the drug to be largely metabolized in 
the rat, rabbit, guinea pig, ferret and man by oxidative 
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deethylation and deacetylation. 	Minor pathways of aromatic 
hydroxylation and cysteine conjugation were also present. 
In species-related metabolism of phenacetin (Smith and Timbrell, 
1974), deacetylation was highest in the rat (21% of dose), 
aromatic hydroxylation to 2-hydroxyphenacetin was highest in the 
ferret (6% of dose) and formation of the 3-cysteine conjugate 
was highest in the rabbit (8% of dose). The pattern of 
conjugation was such that glucuronidation was predominant in the 
rabbit, guinea pig and ferret while sulfate conjugation was the 
major route of metabolism in the rat. The metabolic profile 
differed between large and small oral doses but showed no 
appreciable differences whether the drug was given orally or 
intraperitoneally. 
Different species of animals are affected by methemoglobinemia 
caused by phenacetin to varying degrees (Lester, 1943; Welch et 
al., 1966). This is probably because several deicetylated 
derivatives of phenacetin, (NHPN, 2HPN and PAP), which are known 
to oxidize hemoglobin (Uehleke, 1973), are formed to varying 
degrees in the different species (Smith and Timbrell, 1974). 
In studies of Smith and Griffiths (1976) metabolism of 14-C-
phenacetin in rats fed the drug in their diet over a 3 month 
period, was examined and compared with that in a control group 
of rats receiving only a single dose of the drug. The major 
metabolite was APAP-SULF in both groups of animals. Variance 
was noted in glucuronidation between the groups. Other 
metabolites 	seen 	were 	APAP, 	p-hydroxyglycoanilide, 	p- 
ethoxyglycoanilide and 2HP. 	Excretion of total radioactivity 
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was proportionally reduced when larger doses of phenacetin were 
given. 
1.4.3. INFLUENCE OF CO-ADMINISTERED DRUGS  
More recently chronic dosing studies with phenacetin, caffeine 
and aspirin singly or in combination were undertaken by Macklin 
and Szot (1980) in mice. Histopathological changes indicating 
mild progressive renal papillary necrosis occurred in the 
urinary tract with earliest changes observed in those animals on 
the highest dose of phenacetin. Sulfhemoglobinemia was induced 
in all animals subjected to treatment with phenacetin alone or 
in combination with the other agents. Failure to demonstrate 
carcinogenicity even at these toxic doses of the drugs was in 
agreement with the negative results obtained in similar studies 
in mice described in the NCI Technical report (No.67,1978) cited 
by Macklin and Szot (1980), rats (Woodard et al., 1965; Schmahl 
and Reiter 1954, NCI Tech. report,No.67,1978) and dogs (Schmahl 
and Reiter,1954; Woodard et al., 1965). Yet, other chronic 
dosing studies with phenacetin in rats did present evidence of 
carcinogenicity (Johannson and Angervall, 1976; 1979; Isaka et 
al., 1979). 
The disagreement in these results of very similar experiments 
was suggested to be due to a formulation shortcoming (Macklin 
and Szot, 1980). Administration of the dose through the diet in 
the studies which produced tumours involved pelletization of the 
drug along with the other food ingredients. This process 
requires high temperatures of about 80 C, during which the 
formation of N-oxidation reactive products was claimed to occur. 
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Nitrosocompounds have been known to induce tumours, particularly 
of the nasal cavities (Magee et al., 1976) as well as the 
urinary tract, urinary bladder, renal and mammary glands (Magee 
and Barnes,1967; Magee et al.,1976; IARC, 1978; Ito et al., 
1971). 
Johannsson (1981) studied long term treatment with phenacetin, 
phenazone and caffeine, individually and in combination. Renal 
pelvic tumours occurred only in rats treated with phenacetin, or 
phenazone alone or in combination with caffeine. Half of the 
rats treated with phenacetin, phenazone and caffeine in 
combination developed hepatomas which were considered to be a 
result of the altered metabolism of phenacetin caused by 
phenazone and caffeine. It was postulated that this altered 
metabolism ultimately increased the production of N-
hydroxyphenacetin, a known liver carcinogen (Johansson,1981). 
1.4.4. INFLUENCE OF AGE AND SEX 
Factors of age- and sex-related differences within a species are 
also likely to affect the metabolism of phenacetin. 	The 
hepatotoxicity of paracetamol has been investigated with 
reference to age of the experimental mice by Hart and Timbrell 
(1979) who found paracetamol to be less toxic in neonatal mice 
than in adult animals. This suggests that the development of 
the ability to detoxify reactive metabolites precedes the 
development of the enzyme systems producing them, because 
glutathione levels have been shown to be higher than the levels 
of P-450 in neonates. Green and Fischer (1981) established from 
similarly oriented research that age-related changes in 
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paracetamol metabolism in rats, especially in the extent of 
glucuronidation or sulfation, are complex and depend on the dose 
of the drug and sex of the animal. The influence of age and sex 
on phenacetin metabolism have not been investigated in the 
present study. 
1.4.5. INFLUENCE OF SULFATION INHIBITION  
Interference with metabolism by the administration of compounds 
capable of inhibiting metabolic pathways in order to study the 
ensuing metabolic changes has been carried out previously 
(Meerman et al., 1980; Meermen and Mulder 1981; Mulder and 
Scholtens, 1977). The sulfation pathway, which is a predominant 
metabolic pathway for phenacetin in the rat, has been 
selectively 	inhibited 	by 	2,6-dichloro-4-nitrophenol, 
salicylamide and pentachlorophenol with a simultaneous increase 
in glucuronidation of the substrate, harmol 	(Mulder 	and 
Scholtens, 1977). It has been previously postulated that N-0- 
sulfation, following N-hydroxylation, has been responsible for 
the production of the reactive metabolites of phenacetin which 
combine with tissue macromolecules (Mulder et al.,1977; 1978). 
The analogous N-0-sulfation product of N-hydroxy-2- 
acetylaminofluorene has been similarly implicated in the 
precipitation of toxicity (DeBaun et al.,1970). Inhibition of 
sulfation would therefore be expected to obviate toxicity 
claimed to be caused by the N-0-sulfate conjugate of NHP. This, 
therefore, warrants investigation with a further study of any 
accompanying metabolic changes that occur when sulfation is 
inhibited. 
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FIG. 2: Postulated mechanisms of phenacetin-induced toxicity  
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1.5. POSTULATED MECHANISMS OF PHENACET1N-INDUCED TOXICITY  
Although phenacetin is referred to as a toxic drug, the precise 
mechanism of its toxicity is still to be determined. Studies in 
hamsters (Mitchell et al.,1975) have postulated conversion to 
chemically reactive metabolites via several routes of metabolism 
(Hinson et al.,1979b; 1979c; Nelson et al.,1981). At least 
three different methods of activation have been suggested by 
which phenacetin is expected to be converted to chemically 
reactive metabolites responsible for its toxicity (Fig.2). 
i) Phenacetin undergoes oxidative deethylation by hepatic 
enzymes to form paracetamol, which in turn is converted to a 
chemically reactive nephrotoxic and hepatotoxic metabolite, 
probably NAQ (Calder et al.,1981). 
ii) Hepatic enzymes convert phenacetin 	to 	an 	arylating 
metabolite : plienacetin-3,4-epoxide (Hinson et al.,1977). 
iii) Hepatic enzymes convert phenacetin to N-hydroxyphenacetin 
(Hinson and Mitche11,1976), which could be conjugated as the N-
0-sulfate and N-0-glucuronide, 	both 	reactive electophiles 
(Mulder et al.,1977,1978). Additionally or alternatively NHP 
could be converted to NAQ (Calder et al.,1974). 
In the light of recent research, NHP has been considered to be 
the metabolite of phenacetin most likely to induce nephropathy 
and carcinogenesis (Calder et al.,1973; 1976; Calder and 
Williams,1975; Nery,1971c). The urinary excretion of NHP could 
therefore be indicative of the probable carcinogenicity and 
nephrotoxicity of phenacetin. 
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1.6. SCOPE OF THE PRESENT IN VIVO CHRONIC DOSING STUDY 
The present chronic study was therefore undertaken to elucidate 
more clearly the metabolism of phenacetin and any changes in 
metabolism after prolonged administration of the drug. Such 
factors could be indicative of the mechanism of phenacetin-
induced toxicity. 
An in vivo chronic study in rats was undertaken to monitor the 
excretion levels of the various metabolites of phenacetin, 
during a period of prolonged administration of the drug, at 
regular (weekly) intervals. 
NHP has been implicated as a likely proximal carcinogen of 
phenacetin. Levels of this probably carcinogenic, reactive 
intermediate, which were not determined in other chronic studies 
(Smith and Griffiths, 1976; Smith and Timbrell, 1974), were the 
focus of the present study. 
The effect of the size of dose has already been investigated 
with reference to the extent of metabolism of the drug (Smith 
and Timbrell, 1974) and its toxicity (Boyd and Hottenroth, 1968; 
Boyd, 1971), but these studies had not measured the significant 
metabolite, NHP. The present study also sought to examine the 
influence of size of dose on the formation of NHP. 
The influence of aspirin and caffeine on the metabolism of 
phenacetin was examined. It was of particular interest to 
detect any alteration in metabolism of phenacetin when co-
administered with these drugs. 
Page 26 
The effect of chemicals likely to interfere with certain major 
pathways of phenacetin metabolism (such as sulfation) was of 
interest in this study. The intention was to infer the extent 
of saturation of the existing alternative pathways by 
suppressing the sulfation pathway.The possibility of direct 
interference with the metabolism of phenacetin by these 
chemicals was also of interest. An inhibition of sulfation 
would also be expected to result in diminished formation of the 
N-0-sulfate conjugate of NHP, a known reactive metabolite. 
1.7. ELUCIDATION OF THE METABOLISM OF p-PHENETIDINE IN VITRO  
The toxicity caused by PN, which is known to be hemolytic, could 
be direct or through a subsequent metabolite. 
Although in vitro systems using microsomes have been used to 
study the metabolism and toxicity of several compounds, 
including phenacetin and paracetamol (Hinson et al., 1979a; 
Nelson et al., 1980), metabolic studies using PN as a substrate 
(Buch et al., 1967) which indicated its conversion to 2-HPN, did 
not reveal details of its further metabolism. A study involving 
an in vitro examination of PN metabolism was therefore also 
undertaken in the present work. 
Page 27 
1.8. SELECTION OF AN IN VITRO SYSTEM  
Berry and Friend (1969) successfully 	developed 	enzymatic 
techniques for the isolation of viable hepatocytes and thereby 
introduced a reliable 	in vitro 	system 	for studying the 
metabolism or toxicity of xenobiotics. 
Several substrates have been studied using isolated hepatocytes. 
Benzpyrene (Cantrell and Bresnick, 1972), alprenolol (Moldeus et 
al., 1974), biphenyl (Wiebkin et al., 1976), ethyl morphine 
(Erickson and Holtzman, 1976), amylopyrene, dansylamide, quinine 
(Hayes and Brendel, 1976), barbiturates (Yih and van Rossum, 
1977), amphetamine (Hirata et al., 1977) and methotrexate (Horne 
et al., 1976) are a few examples. 
Isolated hepatocytes were chosen as the in vitro technique for 
the present study because this system has already proven its 
suitability for studies of drug metabolism and toxicity (Thor et 
al.,1978a; 1978b; Moldeus,1978). This is because more cellular 
properties are retained by isolated hepatocytes in comparison 
with microsomal preparations. Both cytochrome P450-dependent 
oxidation reactions (Moldeus et al.,1974; Yih and van Rossum, 
1977) and subsequent conjugation reactions (Wiebkin et al.,1976; 
Billings et al., 1977) are possible. Most importantly, better 
correlation with in vivo results of drug metabolism has been 
established (Billings et al., 1977; Yih and van Rossum, 1977) 
by using isolated hepatocytes in comparison with 900xg 
supernatant. 
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1.9. AIMS OF THE PRESENT STUDY  
i) Study the metabolism of chronically administered phenacetin 
in the rat. 
ii) Examine the influence of dosage size on metabolism. 
iii) Investigate 	the 	effect 	of 	sulfation inhibition on 
phenacetin metabolism and comparatively assess the metabolic 
alterations, if any, seen on administration of phenacetin 
acutely and chronically. 
iv) Detect 	and 	determine 	any 	alteration in phenacetin 
metabolism when phenacetin and aspirin are chronically co-
administered. 
v) Detect 	and 	determine any alteration 	in 	.phenacetin 
metabolism when phenacetin and caffeine are chronically co-
administered. 
vi) Follow the further metabolism of deacetylated phenacetin 
(p-phenetidine) in an in vitro system and to account for its 
disappearance. 
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CHAPTER 2. 	EXPERIMENTAL 
2.1. MATERIALS 
p-Phenetidine (Hopkin & Williams Ltd, England) was redistilled, 
b.p. 	251 C. p-Nitrosophenetole was synthesized (Sec. 	2.1.1.). 
N-Hydroxyphenacetin 	and deuterated N-hydroxyphenacetin were 
gifts from Dr. S. McLean (School of Pharmacy, University of 
Tasmania). 2-Hydroxyphenetidine, N-acetyl-4-aminobenzoic acid 
and N-butyry1-4-aminobenzoic acid were gifts of Mr. M. Veronese 
(School of Pharmacy, University of Tasmania). 
The glucuronide, sulfate, cysteinyl and mercapturate conjugates 
of paracetamol were gifts from Dr. K. Henderson (Sterling 
Winthrop, Newcastle-upon-Tyne, Great Britain). 
Extract of Helix pomatia (beta-glucuronidase plus arylsulfatase) 
was obtained from Boehringer, Mannheim, Germany. Fluorescent 
silica gel (Schleicher and Schull type G7, size 10-40 ) was 
coated (0.25 mm thick) on to glass thin layer chromatography 
plates (20 x 20cm). 
Collagenase Type IV and Bovine Serum Albumin (BSA) essentially 
fatty acid free (Sigma Chemical Company, U.S.A.) were employed 
in hepatocyte isolation. 
Diazomethane was prepared fresh when required for methylation 
from p-tosylsulfonylmethylnitrosamide by the method of Vogel 
(1956), and used as the ethereal solution. 
Drugs were of B.P. grade. All other chemicals and solvents were 
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of A.R. grade and purchased commercially. 
2.1.1. SYNTHESIS OF p-NITROSOPHENETOLE  
p-Nitrosophenetole was synthesized by a modification of the 
method of Vogel (1959). p-Nitrophenetole (500mg, 0.003 mole) 
was dissolved in ethanol (99.5% v/v, 16m1). Ammonium chloride 
(640 mg, 0.012 mole) dissolved in water (3m1) and zinc powder 
(780mg, 0.012 mole) was added. 
The reaction mixture was stirred vigorously at room temperature 
for 90 min and checked for completion by thin layer 
chromatography on a silica gel coated miniplate developed in 
ether and visualized with ferric chloride (2.5% w/v in M/2 HC1). 
The reaction mixture was filtered and the precipitate washed 
with ice cold ethanol. The filtrate was transferred to a 
separating funnel. A saturated solution of sodium chloride was 
added and the mixture shaken thoroughly. 
Chloroform (2x25 ml) was used to extract the salted-out p-
nitrosophenetole and the pooled chloroform extract washed with 
ice cold water (2x25 ml). The chloroform extract was dried over 
anhydrous magnesium sulfate for 1 hour with frequent agitation, 
and evaporated off under vacuum in a rotary evaporator. This 
left a residue of p-nitrosophenetole which was later 
recrystallized 	from 	benzene 	and 	characterized 	by mass 
spectrometry. The recrystallized p-nitrosophenetole was pure. 
It produced a single spot when thin layer chromatographed 
(silica gel-ether) and one peak when gas chromatographed under 
conditions described in Fig. 6. 
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2.2. ANIMALS 
A Hooded Wistar strain of rats fed on a standard laboratory diet 
with water ad libitum were used in all present studies. The 
rats weighed approximately 200 g and were 4 weeks old when used. 
2.3. IN VITRO STUDY 
An in vitro system using freshly isolated hepatocytes from the 
rat was employed. 
2.3.1. HEPATOCYTE ISOLATION 
A modified method incorporating the techniques of Berry & Friend 
(1965) and Seglen (1972; 1973a; 1973b) was adopted (Fig. 3). 
The rat was anaesthetised with pentobarbitone (65 mg/kg; 
prior to surgery. 	After regular respiration was established, a 
mid-ventral incision was made to expose the liver and heparin 
(0.1 ml of 25,000 units/ml) was injected into the inferior vena 
cava to prevent blood coagulation. 
The hepatic portal vein was cannulated with a tube delivering a 
flow 	of 5 ml/min of calcium-free Krebs-Henseleit 	buffer 
(glucose 10mM, carbogen equilibrated, pH7.4, 37 C). 
Immediately after cannulation the buffer flow was increased to 
30 ml/min, the liver was flushed of all blood and the superior 
vena cava was cut open to allow for the drainage of the buffer, 
in situ. 
INTERCELLULAR DISRUPTION 
INCUBATION 
WITH SUBSTRATE 
DECAPSULATION, DISPERSION 
SAMPLING 
HARVESTING 
CENTRIFUGATION 
RECOVERY 
SUPERNATANT I viability count 
RECONSTITUTION OF 
ISOLATED HEPATOCYTES ANALYSIS 
ANAESTHETIZATION 
NEPA R IN I Z AT ION 
CAN NULA TION 
MOUNTING 
PERFUSION 
pH 7-4, 37°C 
carbogen 
Ls Ca-free Krebs - Henseleit, 
15 min 
Ls Krebs-Henseleit, 
5 min 
Krebs-Henseleit 	collagenase, 
45 min 
FIG. 3: Scheme for the isolation and use of hepatocytes  
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The liver was excised from its connective tissue and mounted in 
a perforated plastic receptacle. After 12 min the buffer was 
replaced with Krebs-Henseleit buffer (glucose 10mM, carbogen 
equilibrated, pH 7.4, 37 C). 
After 5 min, collagenase (25 mg in 5 ml buffer) was added to 
give a final concentration of 0.05 % in the perfusate (50 ml), 
which was circulated for a further 45 min. The liver showed 
visible signs of disruption after this period. 
The liver was subsequently transferred into Krebs-Henseleit 
buffer containing BSA (0.1%w/v). The capsule was removed and 
hepatocytes gently shaken free from the connective tissue. 
The suspension of cells and tissue was sieved through nylon 
gauze which retained the connective tissue. The cell suspension 
was allowed to stand for a few minutes and the sedimented cells 
were harvested by decanting off the supernatant liquid. 
After reconstituting with BSA-Krebs Henseleit buffer, the cells 
were allowed to recover under carbogen, in an orbital shaker 
(37 C, 30 min, 120 osc/min). 
Trypan blue (0.2%) was used to estimate the viability count 
which was done in a Neubauer chamber. Viability was between 68% 
and 75%. Cell yield was between 1.3 x 108 to 1.6 x 108. 
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2.3.2. INCUBATION AND SAMPLE COLLECTION 
The isolated hepatocytes from healthy untreated rats were 
reconstituted to give a viable cell concentration of 2.5 x 
10 6 /m1 in Krebs-Henseleit buffer (BSA 1% , pH 7.4). An aliquot 
(5m1) was collected to serve as the blank sample. The substrate 
of •p-phenetidine (3.4 mg in 100 ul ethanol/water:30/70) was 
added to the cell suspension (50 ml) in an incubation flask, 
giving a PN concentration of 0.5 mM, found suitable for 
metabolic studies by McLean (1978). 
A zero time sample aliquot (5 ml) was removed, carbogen flushed 
through the incubation flask and the flask replaced in the 
orbital 	shaker bath (180 osc/min, 37 C), until the next 
collection was due. 	Samples were collected as scheduled in 
Table 1, and the carbogen replenished in the flask after each 
sample removal. 
The aliquots were collected in 15 ml centrifuge tubes kept in 
ice. The aliquot suspensions were centifuged immediately (2500 
rpm for 10 min) and 2 ml duplicate samples of supernatant were 
transferred to centrifuge tubes, frozen immediately in liquid 
nitrogen and stored for assay at -20 C. 
The samples were analysed as outlined in the analytical scheme 
for metabolites of p-phenetidine (Sec. 2.4. and Fig. 4) and the 
results of the analyses are presented in Table 1. 
OXIDATION 
K3Fe(CN)6 
EXTRACTION 
CCl4 
SUPERNATANT 
from Incubate 
+ internal + 
standard 
internal + 
standard 
ENZYMATIC 
HYDROLYSIS 
fi-glucuronidase 
+ arylsulfatase 
37°C 16hr 
BUTYRYLATION 
NaHCO3, 
butyric anhydride 
1. 
EXTRACTION 
CH2Cl2 
GC 
APAP 
PAP 
PN  
ACID HYDROLYSIS 
10N HCl, 100°C, 1hr 
PHENOXAZONE 
FORMATION 
pH 8 -9, room temp. 
EXTRACTION 
CH Cl3 
COLOR DEVELOPMENT 
1N HCl, 70°C 
SPECTROPHOTOME TRY 
X 580 nm 
2HPN 
I 	GC I 
NOPN 
NHPN 
FIG. 4: Analytical scheme for the in vitro metabolites of p—phenetidine  
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2.4. 	ANALYSIS OF THE METABOLITES OF p-PHENETIDINE  
Analytical methods for the extraction and analysis of the 
metabolites of p-phenetidine present in the supernatant of the 
incubate were developed. 
2.4.1. 	DETECTION AND MEASUREMENT OF PHENACETIN, PARACETAMOL,  
p-AMINOPHENOL AND p-PHENETIDINE  
2.4.1.1. HYDROLYSED SAMPLES 
An aliquot (2 ml) of incubate supernatant was buffered to a pH 
of 5.2 with 200 ul acetate buffer (1.1M, pH 5.2), in a 15 ml 
centrifuge tube. Helix pomatia extract (100 ul) and the 
internal standard, p-toluidine (TDN, 50 ug in 50 ul methanol), 
were added. After vortexing briefly (10 sec) the sample was 
hydrolysed (37 C, 16 hr). 
Sodium bicarbonate (120 mg) was added to the sample after 
hydrolysis and vortexed until dissolved to obtain a neutral pH. 
Butyric anhydride (25 ul) was added and the sample vortexed 
frequently over a period of 1 hour after which butyrylation was 
complete. 
The sample was then partitioned with dichloromethane (3 ml), 
vortexed (30 sec) and centrifuged (2500 rpm for 15 min). The 
aqueous upper layer was discarded and the dichloromethane 
extract decanted off after freezing with liquid nitrogen. The 
dichloromethane extract was further concentrated to 50 ul under 
a gentle stream of nitrogen at room temperature. Finally, 1 ul 
of the concentrated extract was gas chromatographed using 
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conditions shown in Fig. 5. Detection of the metabolites was by 
comparison with authentic standards. The concentrations of the 
metabolites were determined by reference to the standard curves 
for phenacetin (linearity: 0.5 ug/ml - 10 ug/ml), paracetamol 
(linearity: 0.5 ug/ml - 10 ug/ml), p-aminophenol (linearity: 0.5 
ug/ml - 5 ug/ml) and p-phenetidine (linearity: 5 ug/ml - 
15Oug/m1), using peak height ratios to internal standard. 
2.4.1.2. UNHYDROLYSED SAMPLES 
The enzyme incubation step was omitted. p-Toluidine was added 
and samples were butyrylated and extracted for analysis as 
above. 
2.4.2. DETECTION AND MEASUREMENT OF p-NITROSOPHENETOLE  
AND N-HYDROXYPHENETIDINE. 
An aliquot of incubate supernatant (2 ml), was transferred into 
a 15 ml centrifuge tube. p-Bromoaniline (BA, 50 ug in 50 ul 
methanol), the internal standard, was added. The method of 
Kiese and Renner (1963) using potassium ferricyanide to oxidize 
the N-hydroxyphene-tidine to p-nitrosophenetole was employed. 
Potassium ferricyanide (25 ug in 25 ul water) was added and the 
sample vortexed for 10 sec. Carbon tetrachloride (1 ml) was 
vortexed for 60 sec with the sample, to extract the required 
metabolites. The sample mixture was then centrifuged (2500 rpm 
for 15 min) and the upper aqueous layer discarded. The sample 
was frozen and the organic phase decanted and concentrated under 
a stream of nitrogen. Finally 1 ul of the extract was gas 
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chromtographed using conditions shown in Fig. 6. Detection was 
by comparison with the authentic standard and concentrations 
could be determined by reference to the standard curve for p-
nitrosophenetole (linearity: 0.5 ug/ml - 10 ug/ml) using peak 
height ratios to internal standard. 
2.4.3. DETECTION AND MEASUREMENT OF 2-HYDROXYPHENETIDINE 
A method based on that of Shahidi and Hemaidan (1969) was used 
to measure 2-hydroxyphenetidine. An aliquot of incubate 
supernatant (4 ml) in a 30 ml stoppered centrifuge tube, was 
acid hydrolysed (1 ml 10 M HC1, 100 C, 1 hr). The hydrolysed 
sample was neutralized with 5M sodium hydroxide (2 ml) and the 
pH adjusted to 8-9 with sodium bicarbonate. After the sample 
was vortexed for 30 sec it was kept at room temperature for 3 hr 
to allow for the formation of the phenoxazone. The tubes were 
cooled 	in ice and extracted sequentially with chloroform 
(2x20 ml). 	The chloroform extracts were pooled and evaporated 
to dryness under vacuum in a rotary evaporator. Color 
development was effected through the addition of preheated 
(70 C) 1M hydrochloric acid (2 ml). The absorbance was read at 
580 nm on a Bausch and Lomb Spectronic 20 spectrophotometer. 
Concentrations were determined by reference to a standard curve 
for 2-hydroxyphenetidine (linearity: 0.5 ug/ml - 25 ug/ml). 
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FIG. 5: GC trace for the metabolites of p-phenetidine in isolated  
hepatocytes  
Metabolites were derivatized (Section 2.4.1.). 
Hewlett Packard gas chromatograph 5700A; 
Column : 0V210 (3% on 100/120 diatomite MQ, glass, 
90cm x 2mm ID); 
col : 200°C; inj : 250°C; det. : 250oC; 
Carrier gas : N 2 (30 ml/min) 
FID gases : Air (240 ml/min), 112  (30 ml/min). 
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FIG. 6: GC trace for the metabolites of p-phenetidine in isolated  
hepatocytes  
Hewlett Packard gas chromatograph 5700A: 
Column : OV-225 (3% on 100/120 diatomite MQ, GLT, 1.0m x 1.8mm ID); 
col. : 132°C; inj. : 150 °C; det. : 200 °C; 
Carrier gas : N2 (20 ml/min); 
FID gases : Air (240 ml/min), H 2 (30 ml/min). 
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2.5. 	IN VIVO STUDY  
2.5.1.1. CHOICE OF DOSE  
Chronic oral daily doses of phenacetin (50 mg/kg), aspirin (50 
mg/kg) and caffeine (10 mg/kg) were chosen on the basis of 
relevance to present day human consumption of the drugs. The 
dose of 100 umol/kg pentachlorophenol, a known inhibitor of 
sulfation, was the same as that used by Mulder and Scholtens 
(1977) to block the sulfation of harmol. An additional, higher 
dose of phenacetin, 500 mg/kg daily, less than half the chronic 
LD 50 dose of 1.12g/kg (Boyd and Hottenroth, 1968), was used to 
examine the effect of chronic dosing on the metabolism of 
phenacetin. 
2.5.1.2. TIME AND ROUTE 
All the drugs in the respective experiments were administered 
orally before midday. Pentachlorophenol was administered 45 min 
prior to the phenacetin dose. Aspirin and caffeine were 
administered with phenacetin. 
2.5.1.3. FREQUENCY AND DURATION  
With the exception of acute pentachlorophenol dosing, which was 
co-administered with phenacetin on the first and seventeenth day 
of treatment, all other drugs were administered daily for the 
duration of the experiments. 
2.5.1.4. FORMULATION 
Caffeine was administered in aqueous solution. 	Phenacetin, 
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aspirin and pentachlorophenol were formulated as suspensions in 
0.25% sodium carboxymethylcellulose. Aspirin and 
pentachlorophenol were prepared fresh before each dose. 
2.5.2.1. DRUG TREATMENTS 
Five different treatments were investigated. A fresh group of 
six rats was used for each investigation except in the instances 
where phenacetin was co-administered with either caffeine or 
aspirin. In these instances each group comprised three rats. 
1. P500 	: Phenacetin (500 mg/kg), administered daily for 29 
days. 
2. P50 	: Phenacetin (50 mg/kg) administered daily for 17 
days. Pentachlorophenol (100 umol/kg) administered on day 17. 
3. P50/PCP : Phenacetin 	(50 	mg/kg) 	co-administered 	with 
pentachlorophenol (100 umol/kg) for one day. 
4. P50/A 	: Phenacetin (50 mg/kg) co-administered with aspirin 
(50 mg/kg) daily for 15 days. 
5. P50/C 	: Phenacetin (50 mg/kg) co-administered with caffeine 
(50 mg/kg) daily for 15 days. 
2.5.2.2. URINE COLLECTION 
During the 24 hr period of urine collection food was withheld 
and the rats were only provided with water ad libitum. 	Urines 
were collected at intervals of 7 days beginning from day 1, 
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using urine collection cages. These cages were of galvanized 
iron with mesh bottoms and mounted over plastic funnels to 
facilitate urine collection. The urine was allowed to run into 
a measuring cylinder, immersed in a Dewar flask containing a 
freezing mixture of ice and salt. 
A minimal amount of distilled water was used to wash the cage 
mesh bottom and the washings were allowed collect in the 
receiver. 
Urines and washings were collected, the volumes noted and the 
urines filtered separately. Aliquots (2 ml) were removed when 
required from each sample for the respective assays, which were 
routinely done after each collection. 
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FIG. 7: Analytical scheme for the urinary metabolites of phenacetin 
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2.6. ANALYSIS OF THE METABOLITES OF PHENACETIN  
The analytical scheme for the metabolites of phenacetin is 
presented in Fig. 7. 
2.6.1. DETECTION AND QUANTITATION OF  
PHENACETIN, 2-HYDROXYPHENACETIN AND 3-HYDROXYPHENACETIN  
Detection and quantitation of phenacetin, 2-hydroxyphenacetin 
and 3-hydroxyphenacetin was by gas chromatography (Figs. 8 and 
9). Analytical procedures were essentially the same as those of 
McLean et al. (1981) as modified by Veronese (1982). 
2.6.2. DETECTION AND QUANTITATION OF  
PARACETAMOL AND ITS CONJUGATES 
Detection and quantitation of paracetamol,and its sulfate, 
glucuronyl, mercapturate and cysteinyl conjugates was by high 
pressure liquid chromatography (Fig. 10). Analytical procedures 
were essentially those of Rumble as cited by Veronese (1982). 
2.6.3. DETECTION AND QUANTITATION OF  
2-HYDROXYPHENETIDINE 
Detection and quantitation of 2-hydroxyphenetidine was carried 
out spectrophotometrically. The method was the same as that 
used in the hepatocyte experiments (Sec. 2.4.3.). 
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FIG. 8: GC trace of 2-methoxyphenacetin (upper band-TLC)  
Hewlett Packard gas chromatograph 5700A; 
Column : SCOT-0V17 (0.45mm ID x 23.65m); 
col. : 205°C; inj. : 200°C; det. : 250°C; 
Carrier gas : 112 (55 cm/sec); FID gases : Air (20 ml/min), 112 (30 ml/min). 
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FIG. 9: GC trace of phenacetin (lower band-TLC)  
Hewlett Packard gas chromatograph 5700A; 
Column : SCOT-0V17 (0.45mm ID x 23.65m); 
col. : 2050C; inj. : 2000C; det. : 2500C; 
Carrier gas : H2 (55 cm/sec); FID gases : Air (20 ml/min), 112 (30 ml/min). 
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FIG. 10: HPLC ANALYSIS OF THE METABOLITES OF PHENACETIN : PARACETAMOL AND  
CONJUGATES OF PARACETAMOL 
15 
COL= : 
SOLVENT : 
FLOW RATE : 
DETECTOR : 
SENSITIVITY : 
INJECTION VOLUME : 
CHART SPEED : 
pBondapak C18 (Waters Associates, 3.9mm ID x 30cm). 
CH3CN/phosphate buffer (10mM, pH 5.0) : 3/97. 
2m1/min (Waters Associates model M45 solvent 
delivery system). 
UV:254nm (Waters Associates model 441 
absorbance detector). 
0.02 - 1.0 AUFS. 
10p1 (Waters Associates model U6K Universal 
Liquid Chromatograph Injector). 
15"/hr (Houston Instruments Omniscribe Recorder). 
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2.6.4. ASSAY FOR N-HYDROXYPHENACETIN 
NHP was detected and quantitated by a modification of an earlier 
method (McLean et al.,1981). An aliquot of urine (2m1) was 
mixed with acetate buffer (200 ul, 1.1 M, pH 5.2), extract of 
Helix pomatia (100 ul) and the internal standard, deuterated N-
hydroxyphenacetin (DNHP,10 ug in 10 ul methanol). 
The urine mixture was incubated at 37 C overnight to hydrolyse 
conjugated metabolites. The incubate was extracted into 
dichloromethane, methylated with diazomethane and separated by 
thin layer chromatography on silica gel as described before 
(McLean et al.,1981). Methylated derivatives of NHP (N-
methoxyphenacetin, NMP), DNHP (deuterated N-methoxyphenacetin, 
DNMP) and 2-HP (2-methoxyphenacetin, 2MP) and 3-HP (3- 
methoxyphenacetin, 3-MP) migrated together (with Rf 0.26) after 
two developments in chloroform. The corresponding urine zone 
was eluted and NMP identified by combined gas chromatography and 
mass spectrometry (GC/MS). The mass spectrum 	of NMP was 
identical to that reported earlier (McLean et al.,1981). 	A 
method based on multiple metastable peak monitoring (Gaskell and 
Millington, 1978) after direct insertion of the sample into a 
double focussing mass spectrometer, set up and operated as 
described by Davies et al. (1982) in a similar assay for 
warfarin, was used for quantifying NHP in rat urine. 
DNMP and NMP produce significant first field free region 
metastable peaks for the successive loss of the elements of the 
acetyl and methoxyl groups (DNMP: m/z 213->139; NMP: m/z 209- 
>135, Fig.11). These metastable peaks are not found in any of 
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the ring-methoxylated metabolites and so could be used to 
directly measure DNMP and NMP in the presence of the other 
methoxylated metabolites of phenacetin. Quantitation was by area 
of the ion current versus time curve during the distillation at 
120 C from the probe (Fig. 12). Blank urine gave no peaks and 
the calibration curve (ratio NHP/DNHP) was linear over the range 
of 0-50 ug NHP added to urine. 
In 	urine 	samples 	collected after the administration of 
pentachlorophenol on day 17 of chronic phenacetin dosing, an 
interfering peak for the 209->135 reaction was encountered. This 
is evident from the disparity in the distillation profiles, 
shown in Fig. 12. A GC/MS analysis was carried out to determine 
the source of interference. Two additional components present 
in the sample were detected and tentatively identified as ethyl 
hippurate and ethyl phenyl-acetyl-glycine. The molecular weight 
of ethyl hippurate was 207 and it gave a large fragment in at 
134, with simultaneous isotope peaks at 208 and 135. 
It 	therefore 	appeared 	that the interference could have 
originated from a 208->135 reaction, as interference peaks are 
known to occur in first field free region metastable studies. 
due to reactions from adjacent precursors to the same daughter 
ion or reactions within fields (Lacey and Macdonald,1977). 
The effect this interfering reaction has on the quantitation of 
NMP could be excluded if the accelerating voltage was changed to 
monitor a hypothetical 210->135 reaction, thereby allowing the 
detection of a 209->135 reaction, but not a 208->135 reaction. 
This was carried out and the samples were then found to have the 
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FIG. 12: N-methoxyphenacetin  
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expected distillation profile, indicating the exclusion of the 
interference (Fig. 13). 
2.7. STATISTICAL ANALYSIS OF DATA 
• A students paired t test was performed for each group of rats in 
order to determine the significance of the observed changes in 
the metabolism of phenacetin with the different treatments. The 
change was considered significant when the value of p was less 
than 0.05. 
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CHAPTER 3. 	RESULTS AND DISCUSSION 
3.1. METABOLITES OF p-PHENETIDINE IN VITRO  
Results of the metabolite analysis obtained from the incubation 
of 0.5 mM p-phenetidine (3.4 mg in 50 ml) with freshly isolated 
hepatocytes are presented in Table 1. 
The 	expected 	metabolites, 	paracetamol, 	p-aminophenol, 
nitrosophenetole and N-hydroxyphenetidine were not detected 
although the sensitivity of the assays used provided detection 
limits of 0.5 ug/ml for the compounds. 
As shown in Table 1 and Fig. 14 the PN was further metabolized, 
indicated by its decreasing concentration over the period of 
incubation. However, the decrease in concentration was 
inadequately accounted for by the formation of phenacetin and 2- 
hydroxyphenetidine, the acetylated and hydroxylated metabolites 
respectively. The N-acetylation of the deacetylated metabolite 
of phenacetin in the rat , namely the N-acetylation of PN, is 
not considered significant, because the N-acetylated metabolites 
of PN are not excreted in the urine of Chester Beatty rats 
gavage fed [ethyl-14-C]-p-phenetidine (Nery,1971b). However, 
from the in vitro experiments performed (using freshly isolated 
hepatocytes from Hooded Wistar rats) in the present work, N-
acetylatio.n of PN was significantly demonstrated. The 
unaccounted for PN was probably converted to certain other 
unknown metabolites or conjugates. 
The relative instability of PN metabolites makes their isolation 
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and investigation difficult. 	Nevertheless, the tendency of 
isolated hepatocytes to hydroxylate and acetylate the xenobiotic 
suggested the elimination of PN via these pathways and explained 
in some measure the increased 2HPN formed in vivo by inhibition 
of sulfation or stimulation of aromatic hydroxylation (Sec. 
3 .2.2.). 
Table 1: Metabolism of p-phenetidine in isolated rat hepatocytes  
CONCENTRATION FOUND IN SUPERNATANT (ug/m1) 
CONTROL 
(without hepatocytes) 
Sample 	Time 
No. 	(min) 	p-phenetidine 
1 	0 64.35 
2 	30 	- 
3 	60 61.58 
4 	90 	- 
5 	120 60.81  
HEPATOCYTE INCUBATE 
p-phenetidine 	phenacetin 	2-hydroxy-p-phenetidine 
	
52.78 	2.08 - 
51.62 3.44 	 - 
49.36 	4.17 0.58 
40.87 3.67 	 0.70 
34.79 	3.26 0.88 
1. Typical of 4 experiments. 
2. Paracetamol, p-aminophenol, p-nitrosophenetole and N-hydroxyphenetidine were not detected. 
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3.2. METABOLITES OF PHENACETIN IN VIVO  
Buch et al. (1967) demonstrated that the major fraction (58%) of 
metabolized phenacetin, in the rat, is accounted for as 
paracetamol and its sulfate and. glucuronide conjugates. From 
the results presented in Table 2 and the graphic 
representations, Figs. 15 to 21, it is seen that a major 
fraction of the phenacetin dose was deethylated to paracetamol 
which was excreted in urine either as free paracetamol or as 
conjugated paracetamol-sulfate and paracetamol-glucuronide. This 
finding was compatible with the findings of earlier in vivo  
studies (Brodie and Axelrod,1949; Nery 1971b). The cysteinyl 
and mercapturate conjugates reportedly found in albino rats of 
the Birmingham Wistar strain, when treated with phenacetin 
(Smith and Griffiths,1976) were not detected in the Hooded 
Wistar strain of rats used in these experiments. 
Paracetamol-sulfate (APAP-SULF) was the major metabolite found 
in the present experiments, while paracetamol-glucuronide (APAP-
GLUC) levels were higher than those reported by Buch et al. 
(1967). 
Hydroxylation of phenacetin was in evidence in the present work. 
N-hydroxyphenacetin (NHP) was found present up to 0.3% of the 
dose of phenacetin. 2-Hydroxyphenacetin (2HP), measured as 
0.07% of the dose of phenacetin in other earlier studies was 
present upto a maximum of 0.06% of the dose of phenacetin in the 
present study. 3-Hydroxyphenacetin (3HP) was not detected. 2- 
Hydroxyphenetidine (2HPN) was also formed to the maximum extent 
of 0.8% of the dose of phenacetin as compared to 6% of the 
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phenacetin dose reported as the sulfate conjugate of 2HPN (Buch 
et al.,1967). The N—deacetylated metabolite 2HPN comprised only 
a minor fraction of the administered dose of phenacetin, an 
observation which has been similarly demonstrated in earlier 
experiments (Brodie and Axelrod,1949; Smith and Williams,1949), 
further indicating the metabolically inert nature of the acetyl 
group of phenacetin as previously suggested by Nery (1971b). 
Unchanged phenacetin was found up to 0.8% of the dose 
administered. 
Table 2: Metabolites of phenacetin in the rat with different treatments  
Days 
TREATMENT 
PERCENTAGE DOSE OF METABOLITES OF PHENACETIN 
APAP APAP-SULF APAP-GLUC NHP 2HP 2HPN P TOTAL 
1 4.05 61.03 22.57 0.046 0.00027 0.779 0.002 88.48 
(0.31) (2.50) (0.91) (0.002) (0.00002) (0.060) (0.000) 
8 5.98 58.95 35.44 0.120 0.00040 0.516 0.011 101.02 
P500 (0.31) (7.48) (4.35) (0.014) (0.00003) (0.031) (0.001) 
15 6.64 52.99 49.76 0.243 0.00085 0.614 0.005 110.25 
(0.61) (0.88) (3.74) (0.020) (0.0001) (0.066) (0.000) 
29 6.98 48.51 55.19 0.314 0.00078 0.750 0.003 111.75 
(0.61) (3.42) (4.99) (0.021) (0.00007) (0.118) (0.000) 
, 
2.72 76.27 13.20 0.102 0.043 0.016 0.145 92.49 
(0.16) (1.70) (1.11) (0.014) (0.002) (0.001) (0.009) 
1 2.34 71.97 \ 15.95 0.111 0.043 0.018 0.374 90.81 
(0.28) (2.24) (0.96) (0.010) (0.011) (0.001) (0.027) 
8 P50 4.13 88.72 15.07 0.099 0.028 0.007 0.392 108.45 
(0.29) (1.61) 	, (1.05) (0.014) (0.002) (0.000) (0.118) 
15 5.14 102.29 15.31 0.144 0.038 0.012 0.306 123.28 
(0.27) (6.77) (1.84) (0.026) (0.005) (0.000) (0.053) 
17* 4.43 75.32 15.33 0.123 0.035 0.018 0.808 96.06 
(0.37) (8.89) (1.23) (0.013) (0.012) (0.001) (0.058) 
Table 2: (continued)  
Days 
TREATMENT 
PERCENTAGE DOSE OF METABOLITES OF PHENACETIN 
APAP APAP-SULF APAP-GLUC 	NHP 2HP 21IPN P TOTAL 
1 3.62 78.7 13.55 0.103 0.038 0.123 0.116 96.25 
(0.57) (1.33) (1.33) (0.007) (0.006) (0.009) (0.022) 
8 P50/A 4.78 74.5 17.74 0.214 0.054 0.170 0.115 97.57 
1 (0.04) (5.64) (1.11) (0.054) (0.004) (0.014) (0.026) 
15 4.77 77.3 16.21 0.221 0.048 0.174 0.090 98.72 
(0.50) (3.05) (0.80) (0.027) (0.002) (0.001) (0.010) 
1 3.92 80.22 13.03 0.115 0.059 0.160 0.158 97.66 
(0.68) (1.53) (0.17) (0.009) (0.017) (0.010) (0.010) 
8 P50/C 4.40 65.91 15.04 0.132 0.039 0.197 0.109 85.83 
(0.57) (4.91) (0.82) (0.023) (0.006) (0.022) (0.006) 
15 4.80 73.33 13.54 0.189 0.058 0.235 0.113 92.26 
(0.33) (12.06) (1.45) (0.029) (0.012) (0.003) (0.014) 
(*) pentachlorophenol (100 umol/kg) adM)inistered. 
Each value is the mean (± SE) of 6 rats, except for P50/A and P50/C where 3 rats were used. 
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P500 	: Phenacetin (500mg/kg) daily. 
P50 	: Phenacetin (50mg/kg) daily, 
: (A) with pentachlorophenol (100pmol/kg) on day 17, 
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(*) p < 0.05; (**) p < 0.01 versus day 1. 
60- 
40- 
20- 
1 	I t 
1 8 	15 17 
I 
1 	8 	15 	22 	29 
** 30- 
• 
20- 
• •- A 
• 
• 
10 - 
P500 
 
P50 
   
   
PE
RC
EN
TA
GE
  D
O
SE
 
P50 /C  
• • • 
P50/A  
	
30- 30- 
20- 	 20- 
• 
10 - 
	 1 0- 
1 	8 	15 	1 	8 	15 
TIME (DAYS) 
FIG. 16: Paracetamol-glucuronide  
Profile of the percentage of phenacetin dose vs. time. 
Refer to the legend of Fig. 15 for particulars of treatments. 
PE
RC
EN
TA
G
E 
D
O
SE
 
• 
0
0
 —
 
0
0
 —
 
0
0
 —
 
• 
- 
L
ii
 
N.
) 	
U.
) 
0
 	
0
 	
0
 	
0
 
a 
 
• 
TOME39DPIEd  
•*
 
ts
.)
 	
LA
) 
0
 	
0
 	
0
 	
0
 	
0
 
(sxva) aka'  
Prof ile of the percentage of phenacetin d ose vs . 
Refer to the legend of Fig . 15 for particulars of treatments . 
• 
.04- 
P50 
.05- 
** • .04- 
.03- 
.02- 
.01- 
22 29 1 8 15 17 
P50/C 
.06-o 
• 
.04- 
.02- 
P500 
.02- 
.0010- 
.0008- 
.0006- 
.0004- 
.0002- 
• 
1 	8 	15 
PE
RC
EN
TA
GE
  D
OS
E 
P50/A 
.06- 
1 
1 	8 	15 1 	8 	15 
TIME (DAYS) 
FIG. 18: 2-hydroxyphenacetin  
Profile of the percentage of phenacetin dose vs. time. 
Refer to the legend of Fig. 15 for particulars of treatments. 
** 
• 0.3- 0.3- 
0.2- 0.2- 
0. 1- 0.1- 
1 	8 	15 	22 	29 	1 
P50/A  PE
RC
EN
TA
G
E
 D
O
SE
 
8 	15 17 
P50/C  
0.3- 
0.2 
0.3 
0.2- 
• 
• 0.1 0. 1 
P500 	 P50 
• 
8 	15 	1 	8 	15 
TIME (DAYS) 
FIG. 19: N-hydroxyphenacetin  
Profile of the percentage of phenacetin dose vs. time. 
Refer to the legend of Fig. 15 for particulars of treatments. 
P500 
.03- 
0.8- * .02 • • • 
0.6- * * 
• 
0.4 - .01- 
0.2 
1 8 15 22 29 1 
P50/A 
.3- .3- 
.2 .2 
• • • 
.1 .1- 
P50 
PE
R
CE
N
TA
G
E
 DO
SE
 
I 
8 
	
15 17 
P50/C  
1 
	 8 	15 	1 	8 	15 
TIME (DAYS) 
FIG. 20: 2-hydroxyphenetidine  
Profile of the percentage of phenacetin dose vs. time. 
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3.2.1. P500 TREATMENT  
In rats dosed with 500 mg/kg of phenacetin daily, between 48% 
and 61% of the dose was excreted as APAP-SULF (Fig. 15). The 
levels of APAP-SULF in the present work were higher than those 
reported by Smith and Timbrell (1974) and declined over the 29- 
day period of study. A progressive depletion, with time, of 
cytosolic sulfotransferase sulfation was therefore inferred. 
The progressive decrease in sulfation was compensated for with a 
simultaneous increase in glucuronidation. Markedly increased 
levels of APAP-GLUC were witnessed during the experimental 
period (Fig. 16). The fraction of dose excreted as APAP-GLUC 
increased from 23 % to 55 % during the dosing period, higher 
than the maximum of 18 % of the dose reported previously (Smith 
and . Timbrell, 1974) 
The glucuronidation of phenacetin with UDP-glucuronyltransferase 
and its sulfation with cytosolic sulfotransferase enzymes of 
phenace tin are competitive pathways of metabolism (Mulder and 
Meerman,1978). Their precedence in the conjugation process are 
inversely related, as demonstrated by Kadlubar et al. (1980), 
Meerman et al. (1980) and Mulder and Scholtens (1977) in studies 
on the regulatory role of sulfation in some biological 
processes. The results of the present work were consistent with 
this inverse relationship and it was seen that glucuronidated 
levels of the drug were notably increased when sulfation was 
suppressed or impaired. 
Smith and Timbrell (1974) found that free APAP is excreted to 
the extent of 5% of the dose of phenacetin. 	In the present 
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study the fraction of unconjugated APAP increased from 4% to 7% 
of the dose of phenacetin, over the experimental period (Fig. 
17). This indicated that not all of the decreased sulfation was 
compensated for by an increase in glucuronidation alone. 
Smith and Timbrell (1974) found 2HP present to the extent of 
3.0% of the dose of phenacetin, but did not measure the 
metabolites NHP and 2HPN in rat urine. NHP and 2HPN are 
significantly relevant to the toxicity of phenacetin. The 
significant increase observed in the formation of 2HP and NHP 
over the experimental period (Figs. 18,19) could be a result of 
induction of the hydroxylation pathway. Auto-induction of 2HP 
formation was obvious in the first fortnight but did not 
increase further in the next. This resulted in its continued 
high level of formation. The induction of formation of NHP 
continued for the entire 29-day period of study and was 
evidenced by the increasingly higher levels of NHP formed. 
NHP had first been reported as an in vivo metabolite in the rat 
by McLean et al. (1981). The arylhydroxamic acids (Miller and 
Miller,1966a ; Weisburger and Weisburger,1973) including NHP 
(Calder et al.,1976) are known to be carcinogenic. The toxicity 
of phenacetin seen on chronic administration could therefore be 
due to the increased formation of NHP. 
However, 	irrespective 	of 	the 	reason for the increased 
hydroxylated products formed, the increased levels of NHP seen 
on administration of the 500 mg/kg dose daily, could well be a 
reason for the chronically induced toxicity of phenacetin. 
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The amount of deacetylated metabolites excreted in the urine of 
rats treated with phenacetin is increased when larger doses of 
phenacetin are administered (Raaflaub and Dubach,1969). A 
higher percentage of the dose of phenacetin present as 2HPN was 
seen on this treatment (P500) in comparison with that seen at 
the lower dose of phenacetin treatments (P50; P50/Ai P50/C). 
Formation of 2HPN exhibited a decreasing trend from 0.8% to 0.5% 
of the phenacetin dose (Fig. 20). This decrease was most 
prominent in the first week and was ostensibly related to the 
precedence of the glucuronidation pathway and the increased 
direct hydroxylation of phenacetin to 2HP and NHP. An increase 
or return to normality after the first week was seen in which 
2HPN reached a maximum of 0.75% of the dose on day 29 (Table 2). 
The percentage of the dose of phenacetin found unchanged in 
urine increased in the first week from 0.002% to 0.011% and then 
decreased over the next three weeks (Fig. 21). It appeared 
logical to assume that the kinetics of metabolism permitted the 
accumulation of phenacetin until steady state had been attained. 
Subsequently induced metabolism converted more free phenacetin 
to its respective metabolites. 
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3.2.2. P50 TREATMENT  
For rats on this dosage regimen a larger percentage of the dose 
was excreted as APAP-SULF, in comparison to the P500 treated 
rats. 	A significant increase in APAP-SULF formation was 
evidenced over the 15 day experimental period (Fig. 15). 	The 
sulfation pathway coped with this dose of phenacetin and its 
induction resulted in increased sulfation. Pentachlorophenol 
(PCP, 100uM)) a known inhibitor of sulfation (Mulder and 
Meerman,1978 ; Meerman et al.,1980) given orally on day 1 of the 
experiment did not alter the level of APAP-SULF in rats 
significantly (Fig. 15), contrary to expectations held on the 
basis of the earlier experiments in acutely dosed rats (Mulder 
and Meerman,1978)- Administered on day 17 of the study, PCP 
inhibited sulfation significantly (p<0.05) though incompletely 
(Fig. 15). The inhibition of sulfation was 27%, compared to 
100% found by Mulder and Scholtens (1977) in their experiments 
using the same dose of PCP intraperitoneally. Therefore, PCP 
administered orally exerts only partial sulfatioti inhibition in 
rats treated chronically with phenacetin. 
The APAP-GLUC levels were much lower in comparison to the P500 
treated rats and remained unaltered at 15% of the phenacetin 
dose (Fig. 16) during the course of the experiment. This was 
not in accordance with the expectation that the glucuronidation 
activity would be reduced as a consequence of the induction of 
the competitive sulfation pathway (Mulder and Meerman, 1978). 
Contrary to expectations therefore, the progressive increase in 
sulfation proceeded with no apparent effect on glucuronidation 
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at this dose. Mulder and Scholtens (1977) have demonstrated the 
suppression of glucuronidation with PCP (100uM, IP) in the rat. 
In the present work PCP (100uM, po) did not affect the 
glucuronidation of APAP. The percentage of the dose of 
phenacetin excreted as APAP-GLUC remained unaffected, thereby 
further establishing the selective sulfation inhibitory effect 
of PCP. 
The percentage of dose excreted as APAP was lower than that seen 
in the P500 treated animals. The APAP fraction increased from 
2.3% to 5.1% of the dose of phenacetin over the study period 
(Fig. 17). PCP did not alter the percentage of the dose of 
phenacetin excreted as APAP 	when 	given 	on day 1, but 
_- 
significantly (p<0.05) lowered it when co-administered on day 17 
of the chronic treatment with phenacetin (Fig. 17). 
A marked decrease in 211P formation in the first week was 
followed by a recovery in the next (Fig. 18). PCP did not alter 
the percentage dose of phenacetin converted to 2HP when given on 
day 1 but lowered it (p<0.05) when co-administered with 
phenacetin on day 17 (Fig. 18). 
Formation of NHP was marginally decreased in the first week and 
then significantly increased in the next (Fig. 19). Induction 
of the N-hydroxylating pathway was noticed in the second week of 
the experiment. 
The levels of NHP were not affected on day 1, but were lowered 
(p<0.05) on day 17 by the co-administration 	of PCP and 
phenacetin. 	PCP 	therefore, 	apparently 	inhibited 	the 
ter 
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hydroxylation of phenacetin to NHP and 2HP in rats treated 
chronically with phenacetin. 
The percentage of dose excreted as 2HPN diminished sharply in 
the first week and partially recovered in the second week of the 
experiment (Fig. 20). PCP did not affect the formation of 2HPN 
significantly on day 1, but caused a steep rise in 2HPN levels 
on day 17 of the experiment when co-administered with phenacetin 
(Fig. 20). 
The partial block of sulfation by PCP resulted in an increased 
formation of 2HPN. This suggested a metabolic shift towards 
increased indirect hydroxylation of phenacetin via PN or 
increased deacetylatcon of 2HP or both. Phenacetin excretion 
was also increased. However, the total increase in excretion of 
2HPN and phenacetin was less than 1 % of the dose of phenacetin 
administered. This did not account for the large decrease (27 % 
of dose) in sulfation caused by PCP on day 17. 
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3.2.3. P50/A TREATMENT  
Aspirin has been shown to be nephrotoxic (Prescott,1970; Nanra 
and Kincaid-Smith,1972b; 1973b) but its possible potentiation of 
phenacetin-induced carcinogenicity and nephrotoxicity require 
further investigation. Altered metabolism of phenacetin 
resulting from an aspirin-phenacetin (Thomas et al.,1973 ; 1974) 
or paracetamol-phenacetin (Whitehouse et al.,1977) metabolic 
interaction have been reported earlier • In the present instance 
when aspirin and phenacetin were co-administered the percentage 
dose of phenacetin excreted as APAP-SULF showed no increase over 
the 15 day period (Fig. 15) as compared to the increased levels 
seen on the administration of the same dose of phenacetin alone. 
The induction of sulfation was interfered with and as a 
consequence APAP-SULF levels were marginally depressed in the 
first week and only partially recovered in the second week. 
These results were in accordance with those of Thomas et al. 
(1974) for phenacetin-aspirin co-administered to rats, 
Whitehouse et al. (1977) for paracetamol-aspirin co-administered 
to mice and Wong et al. (1976) for paracetamol-aspirin co-
administered to hamsters. In these studies the significant 
metabolic effect of aspirin is the reduction of APAP sulfation. 
The 	suppression of sulfation accounted for the increased 
compensatory glucuronidation which yielded higher levels of 
APAP-GLUC in the first week and subsequently slightly lower 
elevated levels (Fig. 16). An increase in glucuronidation was 
also indicative of the enhanced UDP-glucuronyltransferase 
activity that salicylates are reported to cause (Hanninen and 
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Aitio,1968; Diamond et al.,1982). 
Free APAP levels increased from 3.6% to 4.8% of the phenacetin 
dose during the experiment (Fig. 17), a trend similar to that 
observed in the P50 treated rats. 
The hydroxylation of phenacetin to 2HP was increased in the 
first week and lowered marginally in the next (Fig. 18). The N-
hydroxylated product NHP was increasingly formed in the first 
week of treatment and continued a gradual escalation in the next 
week (Fig. 19). The 2HPN fraction increased over the 15 day 
period, most of the increase occurred in the first week of the 
experiment. 
The co-administration of phenacetin and aspirin 	therefore 
resulted in increased aromatic- and N-hydroxylation. This could 
be a result of the direct induction of the hydroxylation pathway 
or a consequence of the partial sulfation inhibition. Analgesic 
mixtures containing aspirin in combination with phenacetin are 
known to be more nephrotoxic than analgesic mixtures in which 
aspirin is excluded or is replaced with phenazone (Nanra et al., 
1980). Johansson (1981) explains the occurrence of renal pelvic 
tumors (only seen in rats treated with phenacetin or phenazone 
alone or in combination with caffeine) as a consequence of the 
altered metabolism of phenacetin, increasing the production of 
NHP, a postulated liver carcinogen. The induced N-hydroxylation 
of phenacetin by aspirin was therefore a noteworthy observation 
of significant interest in the context of potentiated 
phenacetin-induced carcinogenicity and nephrotoxicity. 
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The unchanged phenacetin levels declined over the period of 
study (Fig. 21). The decline was mainly seen in the second week. 
Page 57 
3.2.4. P50/C TREATMENT  
Caffeine continues to be included in analgesic mixtures today. 
The contribution of caffeine to phenacetin-induced toxicity 
needs to be investigated. Research into the mutagenic activity 
and carcinogenic character of caffeine has indicated its 
mutagenic activity in lower organisms and its association with 
bladder cancer (Kuhlmann et al.,1968; Cole,1971), while other 
investigations have found that caffeine seemed to decrease the 
risk of malignancy in rats treated with phenacetin (Granberg-
Ohman et al.,1980). 
In the present work, when phenacetin and caffeine were co-
administered a trend similar to to that observed in the P50/A 
treated rats was witnessed. The APAP-SULF levels showed no 
increase over the 15 day period of study (Fig. 15), quite unlike 
the increased levels of APAP-SULF seen when the same dose of 
phenacetin was administered alone. 
The induction of sulfation was inhibited to a degree by caffeine 
and consequently conversion of phenacetin to APAP-SULF in the 
first week was marginally depressed and only fractionally 
recovered in the second week. 
Increased 	glucuronidation, 	apparent 	in 	the first week, 
compensated for the partial inhibition of-sulfation (Fig. 16). 
Free APAP levels increased from 3.9% to 4.8% of the phenacetin 
dose over the duration of the experiment (Fig. 17). This 
observation was common to the P50 and P50/A treated rats. 
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The hydroxylation of phenacetin to 2HP decreased in the first 
week and then recovered in the next (Fig. 18) an observation 
similar to that seen in the P50 treated rats. Thus caffeine did 
not affect the formation of 2HP. 
A progressive increase in the percentage dose of NHP was 
observed over the 15 day experiment (Fig. 19). The increase was 
more evident in the second week. Contribution to induction of 
N-hydroxylation by caffeine was only marginal, as compared to 
that of aspirin when co-administered with phenacetin. However, 
it still was significantly relevant to the potentiation of 
phenacetin-induced toxicity. 
An increase in the percentage dose of 2HPN occurred over the 
entire 15 day period of study (Fig. 20). Caffeine therefore 
noticeably induced the hydroxylation of phenacetin to 2HPN. The 
unchanged phenacetin levels remained unaltered during the period 
of study (Fig. 21). 
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CONCLUSION 
Sulfation plays an important 	role 	in the metabolism of 
phenacetin in the rat. Most of the drug was accounted for as 
the major metabolite, paracetamol-sulfate. Partial suppression 
of the sulfation pathway with pentachlorophenol increased only 
the fraction of phenacetin metabolized to 2-hydroxyphenetidine. 
It did not increase the formation of 2-hydroxyphenacetin or N-
hydroxyphenacetin. 
As a result of sulfation inhibition, more phenacetin was 
excreted unchanged. The phenacetin metabolized via deethylation 
and the sulfation pathway was not alternatively accounted for 
through any other metabolic pathway. This may indicate a limited 
capacity of the alternative pathways of phenacetin metabolism in 
the rat. 
Autoinduction of hydroxylating enzymes was seen at both high and 
low doses of phenacetin used, though to a lesser degree with the 
lower dose. Induction of N-hydroxylation was enhanced by aspirin 
and caffeine. This significant observation could explain the 
potentiated toxicity encountered in the chronic abuse of 
aspirin-phenacetin-caffeine combinations. The increase in N-
hydroxylation was more likely a result of direct stimulation of 
the hydroxylating enzymes rather than an effect of the 
accompanying partial suppression of sulfation resulting when 
these drugs are co-administered with phenacetin. 
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